Clinical trial · Interventional
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Le20: Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
NCT00398372CI-TRIAL-00004940completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, Non-Hodgkin | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
| Lymphomas: Non-Hodgkin Cutaneous Lymphoma | — | UNRESOLVED | — |
| Lymphomas: Non-Hodgkin Diffuse Large B-Cell | — | UNRESOLVED | — |
| Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | — | UNRESOLVED | — |
| Lymphomas: Non-Hodgkin Mantle Cell | — | UNRESOLVED | — |
| Lymphomas: Non-Hodgkin Marginal Zone | — | UNRESOLVED | — |
| Lymphomas: Non-Hodgkin Peripheral T-Cell | — | UNRESOLVED | — |
| Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epratuzumab | Drug | — | UNRESOLVED |
| Rituximab | Drug | Rituximab | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To characterize the molecular and cell biology of the tumor cells in lymphoma.
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
References
Publications (0)
Data not yet available
No reference posted for this study.